NCE Discovery
poziotinib (pan-HER)
- Most effective pan-HER inhibitor
- Effective for EGFR mutant and HER2 positive/mutant driven solid tumors
- Potent inhibition of EGFR and HER2 exon 20 mutations
belvarafenib (pan-RAF)
- Potent pan-RAF inhibitor
- Effective anti-tumor activities in RAF and RAS mutant driven cancers
HM43239
- Potent inhibitor of FMS-like tyrosine kinase 3 (FLT3) and FLT3 mutants including tyrosine kinase domain.
- Effective therapy for the FLT3 mutants driven cancers, such as AML
HM71224
- Effective Bruton’s tyrosine kinase (BTK) inhibitor
- Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLCγ